Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies

Kidney International

Volumn 81, Issue 12, 2012, Pages 1273-

  Ferro, Hugo H ^a   González, Eliseo B ^b  

^a Bio Sidus   (Argentina)

^b Ciudad Autonoma de Buenos Aires   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; ERYTHROPOIETIN ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT ERYTHROPOIETIN;

ANTIBODY DETECTION; ANTIBODY PRODUCTION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TREATMENT FAILURE; ERYTHROPOIESIS; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; PREVALENCE; PRIORITY JOURNAL; PURE RED CELL ANEMIA; SIDE EFFECT;

EID: 84861711846     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.22     Document Type: Letter

References (4)

1. Praditpornsilpa K, Tiranathanagul K, Kupatawintu P et al. Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int 2011; 80: 88-92.
2. Wish JB. Erythropoiesis-stimulating agents and pure red-cell aplasia: you can't fool Mother Nature. Kidney Int 2011; 80: 11-13.
3. Issaragrisil S. Epidemiology of aplastic anemia in Thailand. Int J Hematol 1999; 70: 137-140.
4. Ferro HH, Donato H, Valtuille R et al. Worldwide pharmacovigilance of a biosimilar product containing epoetin (Hemaxs). Presented at the 8th Annual Meeting of the International Society of Pharmacovigilance. Drug Safety 2008; 31: 913.